Map of Tumor Genetic Actionability in Argentina

NCT06995235 | Active Not Recruiting DMC

• 1 other identifier: 3495
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The study of the human genome laid the foundations for the search for a large number of molecular alterations related to different diseases. The Precision medicine allows us to know molecular alterations that can be detected and targeted for therapeutic purposes. There is little data in Argentina about the incidence and frequencies of alterations molecules associated with the most frequent tumors. Through the selection of a gene panel, analysis of the genetic information obtained analysis allows classifying tumors from a point of view therapeutic. On the other hand, through the same panel, markers of resistance to drugs that allow the incorporation of retreatment therapies. Together with the proposed panel, the ancestry of the patients will be evaluated to determine whether the frequencies of molecular alterations vary between the different ethnic origins of the country.

Conditions

Neoplasms Malignant; Biomarkers

Keywords

panel genes; cancer patients; sequencing

Outcome Measures

Primary Outcomes (1)

• massively parallel sequencing

  Put into operation a massive gene sequencing platform second generation (massively parallel sequencing) for the development of a panel of precision genomic oncology in adult subjects diagnosed with solid tumors assisted at the Italian Hospital of Buenos Aires.

  6 months

Secondary Outcomes (2)

• Ancestry

  12 months

• Tumor genomic actionability map

  36 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

retrospective samples of patients over 18 years of age from different tumors and matrices (e.g. paraffin tissue, fine needle biopsy and fresh tumor)

You may qualify if:

• Subjects 18 years of age or older Subjects diagnosed with cancer due to solid tumors who have a sample of tissue from a previous surgery or biopsy that is sufficient to be able to carry out the study methodology.
• Subjects who agree to sign the informed consent

You may not qualify if:

• Subjects who do not agree to sign the informed consent.

Sponsors & Collaborators

• Hospital Italiano de Buenos Aires: lead

Study Sites (1)

Hospital Italiano de Buenos Aires

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina

Location

Biospecimen

Retention: SAMPLES WITH DNA

Selection of clinically relevant case samples due to the frequency of the pathology

MeSH Terms

Conditions

Neoplasms

Study Officials

• Hernan Garcia Rivello, MD

  Medical Doctor

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: May 16, 2025
• First Posted: May 29, 2025
• Study Start: April 1, 2024
• Primary Completion: December 1, 2025
• Study Completion: April 22, 2026
• Last Updated: May 29, 2025

Record last verified: 2025-05

Locations

AR (1)